CARA: Cara Therapeutics, Inc. - Summary | Jitta
Jitta Wealth
NEW
Log in
Sign up
×
Log in

Cara Therapeutics, Inc.

NASDAQ:CARA

SummaryFactSheetFinancial
Notice
Stock data is unavailable or the company’s delisted.
Price
$15.96
Loss Chance
58.4%
0.01JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Related
The Central and Eastern Europe Fund
NYSE:CEE
4.41
$8.07
53.66%
United States Commodity Index Funds Trust - United States Copper Index Fund
NYSE:CPER
3.32
$20.84
38.04%
Invesco DB Commodity Index Tracking Fund
NYSE:DBC
2.67
$25.19
16.43%
Guggenheim Strategic Opportunities Fund
NYSE:GOF
4.18
$17.02
14.82%
iShares S&P GSCI Commodity-Indexed Trust
NYSE:GSG
2.61
$21.72
28.20%
Jitta Factors
Growth Opportunity (21)
Recent Business Performance (17)
Financial Strength (20)
Return to Shareholders (3)
Competitive Advantage (11)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Revenue and EarningEarning loss detected in 2024
Operating MarginDeclined
SG&A to SalesIncreasing
Key Stats
Jitta Score
Jitta Line
0.01
100.00%
2.62
675.00%
2.62
675.00%
4.41
53.66%
3.32
38.04%
2.67
16.43%
COMPANY DESCRIPTION
As of April 15, 2025, Cara Therapeutics, Inc. was acquired by Tvardi Therapeutics, Inc., in a reverse merger transaction. Cara Therapeutics, Inc. operates as a biopharmaceutical company that focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
About UsCareersHelp CenterLibraryTermsPrivacyContact UsPress

Jitta Dot Com Co., Ltd. is the owner of the copyright of JITTA SCORE, JITTA LINE, JITTA SIGNS, JITTA FACTORS, JITTA LOSS CHANCE and JITTA RANKING. By accessing or using Jitta, you agree to comply with our Terms of Use and agree not to redistribute the information.

All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Any historical returns, backtest statistics or probability projections may not reflect future performance. Neither Jitta nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Fundamental data of companies, historical data, daily updates, financial statements, dividend data and index data are provided by S&P Global Market Intelligence. All stock prices are updated at the end of the day.